Cargando…

Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension

BACKGROUND: Liver dysfunction reflects the status of heart failure, with congestion and low perfusion of the liver serving as causative mechanisms. Previous studies demonstrated relationship between the results of liver function test and the prognosis in patients with heart failure. However, few stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Yasuko, Takeda, Yutaka, Tomimoto, Shigehiro, Tani, Tomomitsu, Narita, Hitomi, Kimura, Genjiro
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873470/
https://www.ncbi.nlm.nih.gov/pubmed/20412580
http://dx.doi.org/10.1186/1471-2466-10-22
_version_ 1782181348141694976
author Takeda, Yasuko
Takeda, Yutaka
Tomimoto, Shigehiro
Tani, Tomomitsu
Narita, Hitomi
Kimura, Genjiro
author_facet Takeda, Yasuko
Takeda, Yutaka
Tomimoto, Shigehiro
Tani, Tomomitsu
Narita, Hitomi
Kimura, Genjiro
author_sort Takeda, Yasuko
collection PubMed
description BACKGROUND: Liver dysfunction reflects the status of heart failure, with congestion and low perfusion of the liver serving as causative mechanisms. Previous studies demonstrated relationship between the results of liver function test and the prognosis in patients with heart failure. However, few studies have examined this relationship in patients with pulmonary arterial hypertension (PAH). METHODS: The subjects were 37 patients with PAH (8 men and 29 women; 18 with idiopathic PAH and 19 with connective tissue disease-associated PAH). A blood test was performed after a 3-month period free from hospitalization and without changes in functional class, treatment, heart sounds, body weight, or heart rate. RESULTS: In a mean follow-up period of 635 ± 510 days, 12 patients died due to heart failure, 2 died due to pulmonary hemorrhage, and 23 patients survived. Cox proportional hazard analyses identified functional class (p < 0.001), plasma concentration of brain natriuretic peptide (BNP) (p = 0.001), and hyperbilirubinemia (serum total bilirubin > 1.2 mg/dL; p < 0.001; hazard ratio = 13.31) as predictors of mortality. Patients with hyperbilirubinemia had a worse functional class (P = 0.003), a higher right atrial pressure (p < 0.001), a higher plasma concentration of BNP (p = 0.004), and a larger Doppler right ventricular index of the right ventricle (p = 0.041). CONCLUSION: Elevated serum bilirubin is a risk factor for death in patients with PAH.
format Text
id pubmed-2873470
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28734702010-05-20 Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension Takeda, Yasuko Takeda, Yutaka Tomimoto, Shigehiro Tani, Tomomitsu Narita, Hitomi Kimura, Genjiro BMC Pulm Med Research article BACKGROUND: Liver dysfunction reflects the status of heart failure, with congestion and low perfusion of the liver serving as causative mechanisms. Previous studies demonstrated relationship between the results of liver function test and the prognosis in patients with heart failure. However, few studies have examined this relationship in patients with pulmonary arterial hypertension (PAH). METHODS: The subjects were 37 patients with PAH (8 men and 29 women; 18 with idiopathic PAH and 19 with connective tissue disease-associated PAH). A blood test was performed after a 3-month period free from hospitalization and without changes in functional class, treatment, heart sounds, body weight, or heart rate. RESULTS: In a mean follow-up period of 635 ± 510 days, 12 patients died due to heart failure, 2 died due to pulmonary hemorrhage, and 23 patients survived. Cox proportional hazard analyses identified functional class (p < 0.001), plasma concentration of brain natriuretic peptide (BNP) (p = 0.001), and hyperbilirubinemia (serum total bilirubin > 1.2 mg/dL; p < 0.001; hazard ratio = 13.31) as predictors of mortality. Patients with hyperbilirubinemia had a worse functional class (P = 0.003), a higher right atrial pressure (p < 0.001), a higher plasma concentration of BNP (p = 0.004), and a larger Doppler right ventricular index of the right ventricle (p = 0.041). CONCLUSION: Elevated serum bilirubin is a risk factor for death in patients with PAH. BioMed Central 2010-04-22 /pmc/articles/PMC2873470/ /pubmed/20412580 http://dx.doi.org/10.1186/1471-2466-10-22 Text en Copyright ©2010 Takeda et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
Takeda, Yasuko
Takeda, Yutaka
Tomimoto, Shigehiro
Tani, Tomomitsu
Narita, Hitomi
Kimura, Genjiro
Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension
title Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension
title_full Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension
title_fullStr Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension
title_full_unstemmed Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension
title_short Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension
title_sort bilirubin as a prognostic marker in patients with pulmonary arterial hypertension
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873470/
https://www.ncbi.nlm.nih.gov/pubmed/20412580
http://dx.doi.org/10.1186/1471-2466-10-22
work_keys_str_mv AT takedayasuko bilirubinasaprognosticmarkerinpatientswithpulmonaryarterialhypertension
AT takedayutaka bilirubinasaprognosticmarkerinpatientswithpulmonaryarterialhypertension
AT tomimotoshigehiro bilirubinasaprognosticmarkerinpatientswithpulmonaryarterialhypertension
AT tanitomomitsu bilirubinasaprognosticmarkerinpatientswithpulmonaryarterialhypertension
AT naritahitomi bilirubinasaprognosticmarkerinpatientswithpulmonaryarterialhypertension
AT kimuragenjiro bilirubinasaprognosticmarkerinpatientswithpulmonaryarterialhypertension